INT120550

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2004
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 27
Total Number 35
Disease Relevance 18.38
Pain Relevance 5.66

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Golgi apparatus (Rock1) cytoskeleton (Rock1) cytoskeleton organization (Rock1)
kinase activity (Rock1) cytoplasm (Rock1)
Anatomy Link Frequency
spinal cord 2
neurons 2
neuronal 1
plasma 1
Rock1 (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 35 99.72 Very High Very High Very High
Intracerebroventricular 11 99.68 Very High Very High Very High
Hippocampus 11 99.64 Very High Very High Very High
Demyelination 56 99.04 Very High Very High Very High
Spinal cord 234 98.86 Very High Very High Very High
Central nervous system 325 98.56 Very High Very High Very High
ischemia 33 98.30 Very High Very High Very High
intrathecal 12 98.16 Very High Very High Very High
Thermal hyperalgesia 9 97.32 Very High Very High Very High
cva 55 96.76 Very High Very High Very High
Disease Link Frequency Relevance Heat
Stroke 171 99.78 Very High Very High Very High
Vasculitis 6 99.72 Very High Very High Very High
Injury 100 99.08 Very High Very High Very High
Demyelinating Disease 62 99.04 Very High Very High Very High
Spinal Cord Injury 176 99.00 Very High Very High Very High
Increased Venous Pressure Under Development 31 98.84 Very High Very High Very High
Disease 236 98.76 Very High Very High Very High
Death 80 98.76 Very High Very High Very High
Cv Unclassified Under Development 54 98.30 Very High Very High Very High
Malignant Neoplastic Disease 40 98.20 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
-secretase provides a new avenue for its therapeutic activation, even though the potential relevance of atorvastatin-mediated ROCK1 inhibition in neurons may not explain the apparent clinical benefits of the drug.
Negative_regulation (inhibition) of ROCK1 in neurons
1) Confidence 0.42 Published 2005 Journal PLoS Medicine Section Body Doc Link PMC543463 Disease Relevance 0.47 Pain Relevance 0.03
More specifically, the data indicate that ROCK1 activation blocks the effects of statins on APP ectodomain shedding, while ROCK1 blockade alone can mimic the effect of statins on APP shedding.
Negative_regulation (blockade) of ROCK1
2) Confidence 0.42 Published 2005 Journal PLoS Medicine Section Body Doc Link PMC543463 Disease Relevance 0.06 Pain Relevance 0
By extension, these data predict that application of statins to neurons might directly or indirectly inhibit ROCK1 activity.
Spec (might) Negative_regulation (inhibit) of ROCK1 in neurons
3) Confidence 0.42 Published 2005 Journal PLoS Medicine Section Body Doc Link PMC543463 Disease Relevance 0.06 Pain Relevance 0
shedding, i.e., activation of ROCK1 blocks basal and stimulated shedding while ROCK1 inhibition apparently relieves a tonic negative influence exerted on shedding by ROCK1 activity.
Negative_regulation (inhibition) of ROCK1
4) Confidence 0.42 Published 2005 Journal PLoS Medicine Section Body Doc Link PMC543463 Disease Relevance 0 Pain Relevance 0.05
Further, in stroke patients, ROCK inhibition by fasudil led to therapeutic effects without severe side effects.
Negative_regulation (inhibition) of ROCK associated with stroke
5) Confidence 0.40 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2500253 Disease Relevance 1.04 Pain Relevance 0.29
Y-27632 (1 mg/kg, an inhibitor of Rho-associated protein kinase (ROCK)), was found to suppress SPC-induced scratching.
Negative_regulation (inhibitor) of ROCK
6) Confidence 0.39 Published 2008 Journal Eur. J. Pharmacol. Section Abstract Doc Link 18289521 Disease Relevance 0.16 Pain Relevance 0.31
Therefore, further evaluation is required to assess the safety of ROCK inhibitors.


Negative_regulation (inhibitors) of ROCK
7) Confidence 0.29 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2500253 Disease Relevance 1.05 Pain Relevance 0.28
In rodent spinal cord injury, fasudil, which is the only clinically available ROCK inhibitor, and Y-27632, another ROCK inhibitor, enhance axonal regrowth and functional recovery (Hara et al 2000; Dergham et al 2002; Fournier et al 2003; Sung et al 2003).
Negative_regulation (inhibitor) of ROCK in spinal cord associated with spinal cord
8) Confidence 0.29 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2500253 Disease Relevance 0.74 Pain Relevance 0.31
Interestingly, it was recently reported that ROCK inhibition by the intracerebroventricular administration of Y-27632 increases anxiety-related behavior in mouse emotional behavior tests (Saitoh et al 2006).
Negative_regulation (inhibition) of ROCK associated with anxiety disorder and intracerebroventricular
9) Confidence 0.29 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2500253 Disease Relevance 0.90 Pain Relevance 0.18
In rodent spinal cord injury, fasudil, which is the only clinically available ROCK inhibitor, and Y-27632, another ROCK inhibitor, enhance axonal regrowth and functional recovery (Hara et al 2000; Dergham et al 2002; Fournier et al 2003; Sung et al 2003).
Negative_regulation (inhibitor) of ROCK in spinal cord associated with spinal cord
10) Confidence 0.29 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2500253 Disease Relevance 0.74 Pain Relevance 0.31
ROCK inhibition by fasudil in patients with cerebral vasospasm does not cause any severe side effects (Shibuya et al 1992).
Negative_regulation (inhibition) of ROCK associated with increased venous pressure under development
11) Confidence 0.29 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2500253 Disease Relevance 0.57 Pain Relevance 0.08
Fasudil, the only clinically available ROCK inhibitor, can be used to predict the expected side effects of ROCK inhibitors in humans.
Negative_regulation (inhibitors) of ROCK
12) Confidence 0.29 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2500253 Disease Relevance 0.56 Pain Relevance 0.10
It is noteworthy that delayed treatment with fasudil also prevents ischemia-induced neuronal death in the CA1 region of the gerbil hippocampus, suggesting that ROCK inhibition has a wide therapeutic time window in the treatment of ischemic stroke (Satoh et al 2007).
Negative_regulation (inhibition) of ROCK in neuronal associated with stroke, ischemia, hippocampus and death
13) Confidence 0.29 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2500253 Disease Relevance 1.08 Pain Relevance 0.29
Fasudil, the only clinically available ROCK inhibitor, can be used to predict the expected side effects of ROCK inhibitors in humans.
Negative_regulation (inhibitor) of ROCK
14) Confidence 0.29 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2500253 Disease Relevance 0.54 Pain Relevance 0.13
Fasudil is currently the only clinically available ROCK inhibitor and was launched in Japan in1995 to treat cerebral vasospasm after subarachnoid hemorrhage (Shibuya et al 1992).
Negative_regulation (inhibitor) of ROCK associated with cv general 4 under development, cva and increased venous pressure under development
15) Confidence 0.29 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2500253 Disease Relevance 1.08 Pain Relevance 0.24
ROCK inactivation also exerts therapeutic effects on CNS injury.
Negative_regulation (inactivation) of ROCK associated with injury and central nervous system
16) Confidence 0.29 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2500253 Disease Relevance 0.74 Pain Relevance 0.37
Inhibition of ROCK causes the loss of the spherical cellular morphology [10].
Negative_regulation (Inhibition) of ROCK
17) Confidence 0.23 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3014295 Disease Relevance 0.23 Pain Relevance 0
Chemical inhibition of ROCK led to a reversal of the rounded morphology and to a decrease in the invasive capacity.
Negative_regulation (inhibition) of ROCK
18) Confidence 0.23 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3014295 Disease Relevance 0.58 Pain Relevance 0
ROCK inhibition leads to an elongated morphology and reduces cen3tel cell invasion
Negative_regulation (inhibition) of ROCK
19) Confidence 0.23 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3014295 Disease Relevance 0.20 Pain Relevance 0
Intrathecal pretreatment with a geranylgeranyl transferase I inhibitor GGTI-2133 (0.001-1.0 nmol) or a ROCK inhibitor Y27632 (0.001-1.0 nmol) completely blocked the mevalonate-induced thermal hyperalgesia.
Negative_regulation (inhibitor) of ROCK associated with thermal hyperalgesia and intrathecal
20) Confidence 0.22 Published 2008 Journal Pain Section Abstract Doc Link 17764839 Disease Relevance 0.69 Pain Relevance 0.80

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox